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Abstract 
Tuberculosis (TB) is a disease of poverty. Ensuring access to health care without risk of financial 
hardship due to out-of-pocket health care expenditures (Universal Health Coverage; UHC) is essential 
for providing accessible care for underprivileged populations, but it is not enough.  
 
The End TB Strategy promotes both patient-centred TB services and social protection measures, which 
aim to mitigate economic hardship on TB patients and their households due to direct medical and 
non-medical expenditures, as well as lost income. The Strategy includes a target that no families 
should face catastrophic total costs due to TB. The indicator linked to this target aims to capture the 
total economic burden linked to TB care, and thus differs from the “catastrophic expenditure on 
health” indicator, a key component of the UHC monitoring framework, aligned to the Sustainable 
Development Goals. 
 
Countries, especially high TB-burden countries, are expected to conduct nationally-representative TB 
patient cost surveys to establish baseline measurements for the catastrophic costs indicator. Findings 
from these surveys should also help identify entry points to develop policies to ensure better financial 
and social protection for TB patients. In this paper, we define the key measurable concepts for TB 
patient cost surveys, notably the types of costs that are captured and related affordability measures. 
We discuss the methods for measuring these notions in the UHC framework and contrast them with 
how they are measured in TB patient cost surveys. 
 1 
1. Introduction and background 1 
 2 
Tuberculosis (TB) remains a major threat to global public health (1). Poor people in resource-3 
constrained settings are most at risk of the disease and its devastating economic consequences (2). In 4 
low- and middle-income countries (LMICs), health care financing is heavily reliant on out-of-pocket 5 
payments. Despite basic TB care being officially free of charge, often partly through vertical funding 6 
mechanisms, TB patients often struggle to afford TB care and incur costs considered to be 7 
“catastrophic” (3-5). 8 
 9 
Universal Health Coverage (UHC), which means that everyone can access the quality health services 10 
they need without financial hardship (6), has long been on the global TB control agenda. Free diagnosis 11 
and treatment have been the cornerstone of global TB control strategies since 1994. The DOTS 12 
Strategy emphasises the use of low-cost, cost-effective tools and interventions to enable affordable 13 
access to quality TB care, which has resulted in 53 million lives saved. Yet, this has been shown to be 14 
insufficient in mitigating economic consequences since non-medical costs and income losses, which 15 
account for a large part of the economic burden for households, are not accounted for within the UHC 16 
monitoring framework (7-9). 17 
 18 
Aligned to the Sustainable Development Goals (SDGs), the World Health Organization´s (WHO) End TB 19 
Strategy has an increased focus on poverty alleviation strategies and social protection initiatives that 20 
cover costs beyond medical expenses, including income security. It also includes a target of no TB-21 
affected families suffering from catastrophic total costs due to the disease (9, 10). To monitor progress 22 
towards this target, the WHO Global TB Programme convened a task force of experts in 2015 to 23 
develop a field-testing protocol and survey instrument for nationally-representative, health-facility-24 
based surveys of costs faced by TB patients ad their households (in shorthand, “TB patient cost 25 
surveys”), building upon the Tool to Estimate Patients’ Costs (11). After field-testing, WHO developed 26 
a Handbook for TB patient cost surveys (10). Countries, especially countries with a high burden of TB, 27 
are expected to adapt and implement these surveys to document the magnitude and main drivers of 28 
costs incurred by TB patients (and their households) and the percentage of TB patients who incur 29 
catastrophic costs as a result of the costs of care, and to monitor these metrics over time. Findings 30 
from these surveys should also help identify entry points to develop policies to ensure better financial 31 
and social protection for TB patients (7). 32 
 33 
As of July 2018, eleven countries had conducted a TB patient cost survey using the WHO methodology 34 
and instrument (12), four surveys are ongoing or near completion, and thirteen countries are planning 35 
 2 
and mobilising funding to conduct such surveys (Figure 1). 36 
 37 
In this paper, we describe the key notions that are measured using these TB patient cost surveys, 38 
notably the types of costs that are captured, and measures of the affordability of these costs in 39 
relation to household income, expressed as occurrence of catastrophic costs and impoverishment. We 40 
discuss the standard methods for measuring these concepts and how they have been adapted in the 41 
TB patient cost survey Handbook, and conclude by highlighting areas for consideration for those 42 
implementing TB patient cost surveys going forward. 43 
 44 
2. Defining economic burden for patients and households 45 
At the heart of the UHC paradigm, is the concept that families should not face undue financial hardship 46 
by accessing health care. This is referred to as financial protection, and it builds on the notion of 47 
affordability of care (13, 14). 48 
 49 
WHO and the World Bank track financial protection through two indicators: high (or catastrophic) 50 
health spending and impoverishment (6). Catastrophic health spending quantifies the proportion of 51 
the population whose resources would be catastrophically reduced by spending on health care (15). 52 
When health care expenditures exceed a given percentage of available income (or expenditure 53 
capacity), they are considered “catastrophic”. The impoverishment approach estimates the 54 
proportion of the population that would be pushed below a defined poverty line due to seeking and 55 
receiving care (16). Generally, catastrophic spending and impoverishment rates are calculated using 56 
household level data captured through population-based surveys. 57 
 58 
3. Measuring catastrophic health spending  59 
 60 
When measuring catastrophic health spending, there are two key variables underlying this approach: 61 
a) total household out-of-pocket payments for health care (numerator, see sections 3.1 and 3.3); b) a 62 
measure of household resources (denominator, see section 3.2).  A ratio of health care costs to a 63 
measure of ability to pay can then be generated (section 3.3), which is compared to a threshold 64 
(section 3.4). 65 
 66 
3.1. Measuring and valuing household costs 67 
 68 
While the UHC indicator uses household surveys to capture health care expenditures (medical costs) 69 
for all conditions, the TB indicator aims to capture instead the total economic burden related to one 70 
 3 
diagnosed health condition only (TB). The UHC indicator focuses on direct out-of-pocket medical costs 71 
only. 72 
 73 
TB patient cost surveys measure three types of cost: direct medical costs, direct non-medical costs 74 
and income loss (indirect costs or opportunity costs). Direct medical costs represent the money 75 
actually spent out of pocket by the patient on medical services such as prescribed medications, 76 
consultation fees, hospitalisation and laboratory tests. These costs are the same as the direct medical 77 
costs measured in the UHC framework.  78 
 79 
Patients (and their carer) often incur other direct costs associated with the utilisation of health care, 80 
such as transport costs to and from the health facility, costs for accommodation and food, which are 81 
referred to as direct non-medical costs. Direct costs are valued by asking patients to recall their actual 82 
expenditure. 83 
 84 
When seeking care and when sick, individuals also incur costs associated with lost productivity due to 85 
illness/disability and time spent seeking care, or looking after a patient instead of working (i.e. carers). 86 
These opportunity costs are referred to as indirect costs in the End TB monitoring framework.  Two 87 
approaches are typically employed to value indirect costs to households: the human capital approach 88 
and the output-based approach (17).   89 
 90 
The human capital approach involves valuing an individual’s time by multiplying the number of hours 91 
spent seeking and receiving care/caring for by their reported or estimated hourly wage rate(18). If 92 
based on reported income, this method can have equity concerns, as it then implicitly values the time 93 
of more productive (higher income) individuals more highly and doesn’t take into account the value 94 
of time lost by individuals who are performing unpaid work or are unemployed or retired (19).  This 95 
can be corrected by using a standard estimated income for these individuals (e.g. the mean for the 96 
lower quintiles based on national statistics or the minimum civil servant wage).  97 
 98 
The output-based approach considers reported changes in income/production (20). This approach is 99 
recommended by WHO for settings predominately characterised by formal economies, where 100 
individuals can reliably report income in monetary terms.   101 
 102 
WHO’s generic instrument for TB patient cost surveys collects data that allows the valuation of both 103 
indirect costs using the human capital approach and the output-based approach (Table 2)(12). The 104 
 4 
End TB Strategy indicator is generally computed based on the output-based approach, with the human 105 
capital approach used in sensitivity analysis. The reason for capturing these data in TB patient cost 106 
surveys is to encourage the valuation of TB-related indirect costs, as such evidence is currently limited 107 
(12, 21-23).  Researchers to date have generally employed the human capital approach to value 108 
productivity losses associated with TB, with varying precision in the estimations of time and income. 109 
However, over one-third of studies included in one recent systematic review that presented indirect 110 
costs did not clearly explain the methods that were used to calculate them (24). 111 
 112 
The economic burden of illness can be measured on the individual level, but it usually makes sense to 113 
look at the economic impact on the whole household especially since other household members also 114 
contribute to direct expenditures and may take time off work to care for the ill person or take their 115 
children out of school to contribute to the household income (25). The affordability of TB costs is also 116 
analysed at the household level due to the impact that TB potentially has on households, as we discuss 117 
below. 118 
 119 
3.2 Measuring ability to pay 120 
Ability to pay is usually measured in terms of income, consumption or expenditure. Income refers to 121 
earnings from employment and sale of assets and receipt of transfers. Consumption refers to spending 122 
on resources (goods and services) consumed by the household. Expenditure excludes consumption 123 
that is not based on market transactions (e.g. home production), and refers to goods or services 124 
purchased but not immediately consumed by the household. (26).  125 
 126 
While reported income is the gold standard measure of ability to pay, in low-income settings, where 127 
employment is mainly outside the formal sector and income is hard to measure reliably, consumption 128 
expenditure is often believed to be a more valid measure of economic resources than income. 129 
However, both remain difficult and costly to collect (27-30).   130 
 131 
In the UHC framework, consumption expenditure is often used rather than income to measure 132 
catastrophic expenditure and impoverishment (6). It can be argued that deducting food spending from 133 
consumption (non-food expenditure) can better capture a household’s ability to pay for health 134 
expenditures (6). Alternatively, no deduction for necessities is made. 135 
 136 
TB patient cost surveys capture either income or consumption expenditure or both. The TB indicator 137 
is computed using the measure of income that is more robust in the specific country setting. For 138 
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countries collecting more than one measure, the more robust will be used for main analysis and the 139 
alternative measures in sensitivity analysis.  140 
 141 
3.3 Generating a ratio of health care costs to a measure of ability to pay 142 
When computing catastrophic spending within the UHC monitoring framework, the numerator is 143 
restricted to direct medical costs (31), and does not measure direct non-medical and indirect costs, as 144 
UHC is mainly about moving towards progressive and equitable health care financing, and national 145 
financing schemes (tax or insurance-based) covering direct medical costs. 146 
 147 
The End TB monitoring framework, on the other hand, is designed to also collect data that can guide 148 
policies on patient-centred service delivery models that can reduce both direct and indirect costs, as 149 
well as social protection schemes for income security and social support. A key element of innovation 150 
of the End TB Strategy “zero catastrophic costs” indicator is thus that the numerator comprises both 151 
direct medical, non-medical and indirect costs. In TB care, indirect costs have been found to account 152 
for a sizeable proportion of total costs (on average 60% of total costs (range: 16-94%) in low- and 153 
middle-income countries (32)), and therefore they are important elements to capture all care-related 154 
expenditures and the economic impact on TB patients from the onset of symptoms to the end of TB 155 
treatment.  The denominator is further defined as annual household income or annual household 156 
consumption expenditure, as outlined in section 3.2 (33).  The resulting ratio is then compared to the 157 
thresholds defined below to determine whether spending is catastrophic.   158 
 159 
3.4 Defining thresholds for catastrophic payments 160 
The catastrophic payment threshold is set as a proportion of income (i.e. households should not spend 161 
more than a pre-specified fraction of their income on health care). When a household’s healthcare 162 
payments exceed a pre-defined threshold, they are defined as catastrophic (15). The choice of the 163 
threshold is so far arbitrary. Various thresholds have been used in the literature: 10% (34), 15% (35) 164 
of household annual income, or 40% of household non-food expenditure (31, 36). WHO and World 165 
Bank now track catastrophic spending on the basis of out-of-pocket expenditures exceeding 10% or 166 
25% of household total income or consumption(6). 167 
 168 
For global monitoring of the End TB Strategy “zero catastrophic costs” indicator, in 2017, WHO has 169 
chosen to use a threshold of 20% of annual household income (12), which was set through expert 170 
opinion voting in the task force.  This is the threshold that is currently used by National TB Programmes 171 
(NTP) implementing TB patient cost surveys and which is annually reported to WHO (1, 37). Countries 172 
that are conducting national TB patient cost surveys are encouraged to undertake sensitivity analyses 173 
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whereby the 20% threshold is altered so that the proportion of patients facing catastrophic costs can 174 
be assessed at different thresholds, and potentially inform a review of the threshold in the future 175 
(Table 2). 176 
 177 
The threshold can be used to help define two measures of catastrophic health spending, both in the 178 
UHC and End TB Strategy framework.  The catastrophic payment headcount measures the incidence 179 
of catastrophic health care costs (i.e. the number (or fraction) of individuals who have been exposed 180 
to catastrophic expenses). The catastrophic payment gap (or excess) measure is used to assess the 181 
intensity or severity of catastrophic spending by looking at the extent to which health care costs 182 
exceed the pre-defined threshold (15) (Table 2).   183 
 184 
The proportion of patients incurring catastrophic costs due to TB is derived from the number of TB 185 
patients with catastrophic costs divided by the number of all TB patients treated at facilities linked to 186 
a national TB programme. This means that the sampling frame is notified patients on treatment rather 187 
than all people with TB in the community, or households in a country. This is for practical reasons since 188 
the only available sampling frame is notified TB patients, and household surveys would require a large 189 
sample size in order to include a sufficient number of prevalent TB cases. 190 
 191 
4. Measuring impoverishment 192 
An additional measure of the affordability of care used for UHC monitoring is impoverishment, or 193 
whether health care costs push households into poverty (or deeper into poverty). In this case, the 194 
threshold is absolute and set in terms of a poverty line. If health care payments cause household 195 
income/consumption expenditure to fall below the poverty line, they are considered “impoverishing”. 196 
The widely used international dollar-a-day poverty line proposed by the World Bank to allow 197 
international comparability, was replaced by USD 1.25-a-day in 2009, at 2005 purchasing power parity 198 
(38). Countries also have their own national poverty lines which may be relevant for comparing 199 
impoverishment over time within a country.  200 
 201 
The incidence of impoverishment measures the increase in poverty due to health care spending. The 202 
poverty gap is the short-fall from the poverty line.  While these are not included in the End TB Strategy 203 
monitoring, countries can include them in the analyses of TB patient cost surveys.  Table 1 provides a 204 
summary of the key measures presented in this section and Section 3.4. 205 
 206 
 207 
5. Towards zero families facing catastrophic costs due to TB: areas for consideration 208 
 7 
 209 
The End TB Strategy target is a first important step in broadening the concept and measurement of 210 
affordability to account not only for medical costs but also for the broader economic impact of TB, 211 
including non-medical and indirect costs.  212 
 213 
However, as illustrated above, the application of the concepts and standard methods of financial 214 
protection warrants further development in the End TB Strategy. The WHO recently published a 215 
handbook based on the experiences and data from the first round of surveys between 2016 and 2017, 216 
which provides comprehensive guidance for conducting facility-based cross-sectional surveys to 217 
assess TB patient costs (12). This would benefit from periodic methodological updates based on multi-218 
country analyses of survey findings and strengthened collaboration with health economists, NTPs and 219 
policy makers. These updates include: methods for calculating confidence intervals for key survey 220 
indicators, adjusted for the sampling design; a regression-based approach for imputing missing costs; 221 
recommendations on the design of a household expenditure questionnaire (to derive a household 222 
income measure based on expenditure); adaptation of the survey instrument to high-income settings.  223 
 224 
There are a number of areas for consideration for those implementing TB patient cost surveys going 225 
forward, including: descriptive analyses of costs that unpack direct medical and non-medical costs, 226 
and indirect costs, as they can provide valuable information to identify entry points for appropriate 227 
polices and interventions to minimise these costs; using both the human capital and the output-based 228 
approach to value indirect costs for comparison and correlation; measuring and comparing income 229 
and consumption expenditure to compute financial protection measures.  Additional approaches and 230 
metrics to the standard End TB Strategy framework methodology include: measuring impoverishment, 231 
computing the catastrophic payment gap, and sensitivity analyses with different percentages of 232 
income thresholds (Table 2). 233 
 234 
Finally, it is important to bear in mind that the cross-sectional study design for a TB patient cost survey 235 
recommended by WHO inevitably focuses on the economic consequences of TB by using a measure 236 
at one point in time, and therefore it fails to capture the long-term economic consequences of the 237 
disease for the household, including the impact on reduced labour supply and productivity, and 238 
household resilience. Coping mechanisms were originally explored as part of the development of the 239 
TB indicator as deemed to be potentially less labour intensive to collect and easier to integrate in 240 
routine surveillance. However, as coping mechanisms are different in different cultures and societies, 241 
it’d be difficult to consider them as a proxy for catastrophic payments. 242 
 243 
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Several research studies are now ongoing that have adapted the WHO generic protocol to a 244 
longitudinal design, including for long-term follow up after TB treatment. These studies will be helpful 245 
for the validation and interpretation of cross-sectional TB patient cost survey data. Separate studies 246 
of non-notified TB patients, e.g. in private care, are required to measure costs in situation where user 247 
charges for clinical care are often higher than in facilities linked to NTPs.  Yet other studies sampling 248 
people with TB who are not under treatment at the time of the study are needed as the current 249 
methodology only includes TB patients who are successfully staying in care. Such studies can be 250 
conducted in the context of tracing patients who are lost to follow up (e.g. initial loss to follow up or 251 
loss to follow-up during treatment) by reconnecting them with treatment and explore reasons for loss 252 
to follow up. Assessing costs incurred by such patients may shed light on costs related to the disease 253 
and disability that are not linked to care seeking, and costs of living with TB without getting proper 254 
care. 255 
 256 
Conclusions 257 
 258 
In this paper, we have described economic burden and affordability concepts and measurements that 259 
underlie the End TB Strategy indicator of “zero catastrophic costs” due to TB, and have highlighted the 260 
novel elements of this indicator in relation to approaches used in the UHC monitoring framework. 261 
Further findings from national surveys, multi-country analyses and research using alternative 262 
approaches will be important in providing further evidence to refine metrics and methodology for 263 
country-level implementation and global monitoring.  264 
 265 
The conventional concepts and measurement of “financial protection” of the UHC monitoring 266 
framework have been taken a step forward in the End TB Strategy to ensure metrics are able to 267 
capture the total economic burden of TB on patients and families. This approach has the potential to 268 
inform the design of financing and implementation of both health care and social protection policies 269 
that aim to prevent both direct and indirect costs of care, and ultimately ensure that TB care is truly 270 
affordable for TB patients.  271 
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Figure 1: Global implementation of tuberculosis patient cost surveys following the World Health 
Organization methodology, as of July 2018. 
 
 
 
 
Source: WHO Global TB Programme, July 2018 
 
 
Table 1: Summary of key measures of catastrophic health spending and impoverishment for general 
UHC monitoring. 
 
1. Concept of catastrophic health expenditure: key indicators 
Indicator What it is measuring 
Catastrophic payment headcount (or 
incidence of catastrophic health 
expenditure) 
Proportion of households in a population who face 
catastrophic health expenditure 
Catastrophic payment gap (or excess or 
mean positive catastrophic overshoot) 
Percentage points by which household spending on 
health exceeds the threshold for catastrophic health 
expenditure 
2. Concept of impoverishment due to health spending: key indicators 
Indicator What it is measuring 
Incidence of impoverishment 
Proportion of households in a population who fall 
into poverty due to health care spending 
Poverty gap (or increase in the depth of 
poverty) 
 
Percentage points by which a household falls 
further into poverty due to health care spending 
Source: Adapted from Saksena et al 2014 (39). 
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Table 2: Summary of recommended and additional approaches, metrics and valuation methods for TB 
patient cost surveys based on the World Health Organization methodology (12). 
 
Approach/valuation method/metric Recommended Additional 
Costs 
Direct 
Cost disaggregation 
(medical/non-medical) 
• 
 
Indirect 
Human capital approach •  
Output-related approach •  
Measure of 
living 
standard 
Income 
Reported individual and 
household income pre and 
post-TB diagnosis 
• 
 
Asset-based income •  
Consumption expenditure •  
Measures of 
financial 
protection 
Catastrophe 
Catastrophic Payment 
Headcount 
• 
 
Catastrophic payment gap  • 
Impoverishment 
Incidence of 
impoverishment 
 • 
Depth of poverty  • 
Threshold 
Catastrophe 
20% threshold • 
 
Sensitivity analysis with 
different percentages of 
income threshold 
•  
Impoverishment 
International poverty lines 
(e.g. USD 1.25-a-day in 
2005 PPPs) 
 • 
National/locally defined 
relevant poverty lines 
 • 
 
